Eli Lilly and Company $LLY Shares Sold by Aware Super Pty Ltd as trustee of Aware Super

Key Points

• Aware Super Pty Ltd reduced its stake in Eli Lilly and Company by 2.9%, now owning 69,204 shares valued at approximately $53.95 million, making it the company's 20th largest holding.
• Eli Lilly's stock is currently valued at $826.20, with a market capitalization of $781.97 billion and a PE ratio of 54.00, reflecting strong financial performance.
• The company's recent earnings report surpassed expectations, with a quarterly EPS of $6.31 compared to analysts' predictions of $5.59, and revenue of $15.56 billion, up 37.6% year-over-year.

Aware Super Pty Ltd as trustee of Aware Super reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,204 shares of the company's stock after selling 2,086 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Aware Super Pty Ltd as trustee of Aware Super's investment portfolio, making the stock its 20th biggest holding. Aware Super Pty Ltd as trustee of Aware Super's holdings in Eli Lilly and Company were worth $53,947,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Covestor Ltd grew its stake in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company's stock valued at $352,000 after purchasing an additional 85 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock valued at $14,866,000 after purchasing an additional 3,696 shares during the last quarter. Finally, Warner Financial Inc. grew its stake in shares of Eli Lilly and Company by 129.2% in the 1st quarter. Warner Financial Inc. now owns 1,123 shares of the company's stock valued at $927,000 after purchasing an additional 633 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 1.7%

Eli Lilly and Company stock opened at $826.20 on Thursday. The stock's 50 day moving average price is $745.96 and its 200 day moving average price is $766.28. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market cap of $781.97 billion, a PE ratio of 54.00, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. JPMorgan Chase & Co. decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the company an "overweight" rating in a research note on Thursday, October 9th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Finally, Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $948.06.

Insider Activity at Eli Lilly and Company

In other news, EVP Daniel Skovronsky bought 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.